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Results: Mean age at presentation was 51±26 and 37 patients were male. TR grade was
>3 in 92%. Main etiology was traumatic (n=37, 62%), non-iatrogenic in 19 (mostly related
to motor vehicle accident) and iatrogenic in 18 (mostly related to right ventricular biopsy).
Clinical presentation was often severe: 57% were in NYHA class >II, 33% had a history
of congestive heart failure (CHF) and 40% of atrial fibrillation (AF). Compared to
expected survival of US matched population, an excess mortality was observed even
after exclusion of 11 patients in whom associated diseases could have affected the sur-
vival (3.8% yearly, p=0.02). Patients asymptomatic at presentation also experienced a
high incidence of TR-related complications (symptoms or CHF, AF, surgery or death,
75±15% at 10 years) predicted by severe enlargement of right-sided chambers (at 5
years 86±9 vs. 39±11%, p<0.01). Natural history started from date of occurrence of the
flail also showed high complication rates (69±9% at 15 years). Etiology of TR did not
influence the outcome. Tricuspid surgery was performed in 33 patients (55±7% at 5
years) and repair was performed in most patients (82%) with low mortality (3%). Despite
frequently refractory AF, surgery allowed symptomatic improvement in 88%.
Conclusion: TR due to FL is a serious disease associated with excess mortality and
high morbidity. Tricuspid valve repair can often be performed with low risk allowing symp-
tomatic improvement. These results suggest that surgery should be considered early in
the course of the disease before occurrence of intractable heart failure, particularly in
patients with dilatation of right-sided chambers.
1030-138 Valvular Regurgitation Predicts Cardiovascular 
Mortality and Morbidity Among American Indians: The 
Strong Heart Study
Felizen S. Agno, Marcello Chinali, Lyle G. Best, Jonathan N. Bella, Barbara V. Howard, 
Elisa T. Lee, Richard B. Devereux, Weill Medical College of Cornell University, New York, 
NY
Background: Valvular regurgitation has been extensively examined in cross-sectional
studies but there are few data on its association with cardiovascular (CV) morbidity and
mortality in population-based samples. Methods: In 3,199 participants (60±8 years, 64%
women, 45% hypertensive, 47% diabetic) without prevalent CV disease, valvular stenosis
or prostheses who had echocardiograms in the 2nd Strong Heart Study examination, Cox
proportional hazards models were used to estimate hazard ratios (HRs) associated with
isolated mitral regurgitation (MR) or aortic regurgitation (AR) or combined MR and AR
(MAR) for each outcome. Results: Among participants, 587 (18.3%) had MR of any
degree, 198 (6.2%) had any degree of AR and 139 (4.3%) had MAR. During 9,926 per-
son-years of follow-up, 9.0% of participants (N=289) had CV events, 12.4% (N=396) died
(28.9% of CV causes and 5.8% died suddenly). In multivariable analyses controlling for
age, gender, systolic and diastolic blood pressure, body mass index, glucose, insulin,
creatinine, lipid profile, smoking, diabetes and hypertension, MAR but not isolated MR or
AR was associated with increased risks of incident CV events (HR 2.0), CV death (HR
2.8), sudden death (HR 5.9) and all-cause death (HR 1.8)(all p<0.05, see Table for 95%
CIs). Conclusions: In a population-based sample of middle-aged and elderly adults, co-
existent MR and AR (MAR) is prevalent (4.3%) and is independently associated with
increased risk of all-cause and CV death and events. 
1030-139 Prevalence and Correlates of Mitral Regurgitation in 
Hypertensive Patients: The HyperGen Study
Zhi Bin Li, Richard B. Devereux, Jennifer E. Liu, Dalane W. Kitzman, Albert Oberman, 
Paul N. Hopkins, Charles C. Gu, Donna K. Arnett, Weill Medical College of Cornell 
University, New York City, NY
Background: The prevalence and correlates of mitral regurgitation (MR) for hypertensive
patients in a population-based sample have not been well described.
Methods: MR was accessed by color Doppler of echocardiograms in 2172 hypertensive
and 367 normotensive adults from the population-based Hypertension Genetic Epidemi-
ology Network (HyperGEN) study.
Results: Mild MR was present in 15.3%, moderate in 2.5% and severe in 1.0% of hyper-
tensive participants, versus 15.7%, 8.5% and 0.3% of normotensive adults (p=NS).
Among hypertensive patients, MR prevalence was associated with older age. After
adjusting for the effect of age, MR was associated with Caucasian ethnicity, lower body
mass index, higher systolic blood pressure, coronary artery disease, larger left atrium
size, mitral and aortic valve diseases (all p<0.05). In ANOVA and multivariate analyses
adjusted by covariates such as age, gender, body mass index, blood pressure, aortic
regurgitation, mitral valve and coronary artery disease, mild MR was associated with
increased LV mass index (95±23 vs. 87±19 g/m2) (p<0.01); moderate to severe MR were
associated with increased LV diastolic diameter (5.5±0.9 vs. 5.1±0.5 cm) and LV mass
index (105±26 vs. 87±19 g/m2), lower LV systolic function indices such as ejection frac-
tion (54±15 % vs. 62±7 %) and stress-corrected midwall shortening (99±22 % vs.
105±12 %) (all p<0.05). MR prevalence was not associated with gender, controlled or
uncontrolled hypertension, antihypertensive medication, diabetes, serum creatinine,
albumin, cholesterol and triglyceride levels (all p=NS).
Conclusions: This study showed that MR prevalence was nearly 19% among hyperten-
sive patients. It was associated with older age.After adjusting the effect from age, it was
also associated with Caucasian ethnicity, larger left atrial size, cardiovascular diseases,
systolic blood pressure difference and lower body mass index. The presence and severity
of MR were positively related to increased LV hypertrophy, greater LV dilatation and dys-
function. MR prevalence was unrelated to gender difference, diabetes, isolated hyperten-
sion and antihypertensive medication.
1030-140 Patent Foramen Ovale: A New Factor Associated With 
Progression of Carcinoid Heart Disease
Nicolas Mansencal, Emmanuel Mitry, Franck Digne, Jean-François Forissier, Thierry 
Joseph, Pascal Lacombe, Philippe Rougier, Olivier Dubourg, Hôpital Ambroise Paré, 
Boulogne, France
Background: Several studies have demonstrated that serotonin and chemotherapy were
associated with the progression of carcinoid heart disease (CHD). The aim of this pro-
spective study was to assess the role of patent foramen ovale in the progression of CHD.
Method: In 30 consecutive patients (mean age 58 years, range 40-74, 50% women) with
carcinoid syndrome, we performed serial (77) echocardiographic studies. The echocar-
diographic following parameters were systematically assessed: 1) right-CHD, 2) left-CHD,
3) right to left shunting through a patent foramen ovale (PFO) using contrast echocardio-
graphy at rest and after cough test or Valsalva maneuver.
Results: Mean follow-up was 24 months (range: 12-48 months). At baseline, echocardio-
graphy revealed 10 pts (33%) with right-CHD and 4 pts (13%) with left-CHD (Table). At
the end of follow-up, the incidence of right-CHD, left-CHD was respectively 53% (16 pts)
and 33% (10 pts). The baseline and follow-up frequencies of PFO were respectively 27%
(8 pts) and 43% (13 pts). The presence of PFO was strongly associated with the progres-
sion of both right- and left-CHD (p=0.001). The metabolite of serotonin (urinary 5-HIAA,
p=0.002) and plasmatic chromogranin A (p=0.002) levels were also predictive factors of
progression but not chemotherapy (p=0.7).Conclusion: Our data suggest that PFO is a
new important factor of carcinoid heart disease progression and should be systematically
researched by serial contrast echocardiographic studies.
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1048-136 Long-Term Results With the St. Jude Medical Aortic 
Valve: A 25-Year Experience
Robert W. Emery, Kit V. Arom, Christopher Krogh, Lyle D. Joyce, Minnesota 
Cardiovascular & Thoracic Surgeons LLC, St. Paul, MN
BACKGROUND: From 10/77 – 10/02, 2983 patients (age range 17-94 years, average
age 65 ± 13) underwent aortic valve replacement (AVR) with the St. Jude Medical (SJM)
heart valve. Concomitant coronary bypass was performed in 1239 (42%) patients.
METHODS: Cardiac Surgical Associates has maintained an independent database of
our patients having valve replacement with the SJM prosthesis since the world’s first
implant in 10/77. Patients were contacted by questionnaire and/or phone from 11/02
through 6/03. Hospital course and valve-related events were verified by patient chart
review and/or physician contact.
RESULTS: Operative mortality was 4% (AVR 3%; AVR/CAB 6% of which 15 (12% were
valve related. Total follow-up (94%) was 21,742 patient years (range 1 month to 24.8
years, average 7 ± 5 years). At 25 years, overall patient freedom from late mortality was
61% and from late valve-related mortality 93%. Freedom from thromboembolic events
was 86%; from bleeding events 81%; from endocarditis: 98%, and from valve thrombosis
99%; and from reoperation 99%. Reoperation was carried out in 51 patients (2%) for
suture closure of paravalvular leak (n=4), valve replacement (34) and debridement of
valve (13). There were no structural failures.
CONCLUSION: The SJM valve has proven to be an effective and durable heart valve
prosthesis with a low event rate over the long term.
1048-137 Impact of Valve Prosthesis-Patient Mismatch on 
Pulmonary Arterial Pressure After Mitral Valve 
Replacement
Mingzhou Li, Jean G. Dumesnil, Patrick Mathieu, Philippe Pibarot, Laval University, 
Sainte-Foy, PQ, Canada
Background: Pulmonary arterial (PA) hypertension is a serious complication of mitral
valve disease and it is a major risk factor for poor outcome following mitral valve replace-
ment (MVR). We hypothesised that valve prosthesis-patient mismatch (PPM) might be a
determinant of PA hypertension after MVR. Methods: Systolic PA pressure was mea-
sured by Doppler-echocardiography in 56 patients with normally functioning mitral pros-
thetic valves at 24±14 months after MVR. Mitral valve effective orifice area (MVA) was
determined by the continuity equation and indexed for body surface area. Results: Sev-
enty one (71) percent of patients had PPM defined as an indexed MVA < 1.2 cm2/m2.
Thirty patients (54%) had a systolic PA pressure > 40 mmHg and 13 patients (24 %) had
a systolic PA pressure > 50 mmHg. There was a good correlation (r=0.64) between sys-
tolic PA pressure and indexed MVA (see figure). The average systolic PA pressure and
prevalence of PA hypertension (PA pressure > 40 mmHg) were 34±8 mmHg and 19% in
Association of Valvular Regurgitation With Morbidity and Mortality
Events MR alone
HR (95% CI)
AR alone
HR (95% CI)
Combined MR and AR
HR (95% CI)
CV Events 1.3 (0.9 to 1.8) 1.3 (0.8 to 2.1) 2.0 (1.2 to 3.2)
CV Death 1.4 (0.8 to 2.3) 1.4 (0.7 to 2.8) 2.8 (1.4 to 5.5)
Sudden Death 2.2 (0.7 to 7.1) 1.2 (0.2 to 6.5) 5.9 (1.4 to 25.6)
All-cause Death 1.2 (0.9 to 1.6) 1.1 (0.7 to 1.6) 1.8 (1.2 to 2.8)
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patients with no PPM versus 46±8 mmHg and 68% in patients with PPM (p<0.001). Con-
clusions: PPM is associated with persisting PA hypertension after MVR. The clinical
implications of these results are important given that PPM is frequent in patients under-
going MVR and could largely be avoided by using a prospective strategy at the time of
operation. 
1048-138 Edge-to-Edge Mitral Repair Seems to Induce Functional 
Restriction
Catherine Sportouch, Valérie Rauzy, Philippe Rouvière, Franck Raczka, Jean-Marc 
Frapier, Jean-Marc Davy, Bernard Albat, Hopital Arnaud de Villeneuve, Montpellier, 
France
Objective: Edge-to-edge mitral repair could be a limiting factor for exercise tolerance due
to increasing transmitral gradient during stress test.
Methods: Between June 2000 and December 2002, 28 patients with an echographic
grade 3 to 4 mitral regurgitation were operated on according to Alfieri's technique. The
mean age was 64.3 ± 16.2 years. In 17 cases, there was a bileaflet prolapsed degenera-
tive valve, in 7 cases there was a pure or associated ischemic mitral regurgitation, and in
4 cases an endocarditis. The operation consisted on suturing the free margins of the pro-
lapsed segments of the two leaflets in 100% of cases. Associated procedures were Car-
pentier's ring annuloplasty in 62.4% and CABG in 14.3% of cases. After a mean of follow-
up of 7.5 months, all patient were seen at the outpatient clinic for a clinical evaluation, an
echocardiogram at rest and at peak exercise, and a cardio respiratory exercise testing
with maximal oxygen uptake (VO2 max) recording.
Results: There was no early or late death. Improvement of the NYHA class was
observed in all patients with a conversion from a mean preoperative value of 3.1 ± 1 to a
postoperative value of 1.3 ± 0.5 (p< 0.0001). Eighty-two per cent of patients have had no
residual mitral regurgitation. In all cases there was a lowering of the arterial systolic pul-
monary pressure from a mean of 45 ± 19 mmHg preoperatively to 36 ± 11 mmHg postop-
eratively (p= 0.02) and LVEF remained unchanged from 59 ± 10 to 63 ± 12 (p=0.17). The
mean transmitral gradient was 3.6 ± 1.6 at rest and increased to 8 ± 3.3mmHg during
peak exercise (p<0.0001). The mean mitral area was 2.4 ± 0.1cm2. Among the 21 inter-
pretable cardio respiratory exercise testing, 57.1% of the patients had normal exercise
tolerance (mean VO2 max >85% normal value), 33.3% patients had a moderate cardio-
genic limitation (69.8% mean VO2 max), and 9.6% of the patients had a muscular exer-
cise limitation due to exercise deconditioning.
Conclusion: According to these results, this technique seems to induce a restrictive
aspect of the repair as demonstrated by the valve area, the transvalvular gradients and
the limitation of VO2 max, but its impact on clinical status seems moderate.
1048-139 Impact of Associated Coronary Disease on Hospital 
Survival of Patients With Valvular Heart Diseases in New 
York State (1983-2000)
Phyllis G. Supino, Amanda D. Konstam, Jeffrey S. Borer, Weill Medical College of Cornell 
University, New York, NY
Background: Coronary artery disease (CAD) is an important cause of perioperative and
late mortality among patients (pts) who undergo surgery (VS) for valvular heart disease
(VHD). However, no data exist regarding recent temporal trends in CAD prevalence and
its relation to mortality in VHD; also, the benefit of bypass grafting (CABG) plus VS for
CAD+VHD is not well defined. Methods: We conducted a longitudinal analysis (1983-
2000) of records from the New York Statewide Planning and Research Cooperative Sys-
tem (SPARCS) inpatient database; each bore a principal or secondary ICD-9 code for
VHD ±CAD ±CABG. Linear regression was used to model temporal trends in CAD and
hospital death rates (MORT) among pts with and without CAD and/or CABG. Chi Square
and multivariate logistic regression analyses defined the relation of MORT to CAD,
CABG and selected clinical factors. Results: We identified 1,162,318 pts with VHD;
333,359 (33%) had associated CAD; 63,250 pts died in the hospital. In VHD pts, CAD
increased over 18 years at 1993 pts/yr (linearized rate, p<.001) and was associated with
higher MORT (25,245/383,359 [CAD, 6.6%] vs 38,005/778,959[no CAD, 4.9%] p<.001).
VS was performed in 77,564 pts; 35,974 (46%) had associated CAD and 27,670/35,974
(76.9%) of these underwent VS+CABG. This proportion did not change during the 18-
year interval (NS). Among VS pts, avg. MORT varied with CAD and CABG: no
CAD=5.8%, CAD/No CABG=8.7%, CAD/CABG=10.3%, p<.001. MORT in all subgroups
decreased similarly over time (p<.001). Independent MORT predictors in VS+CAD were
concomitant CABG(p=.007), age >65 years, female gender, non-white race, CHF, mitral
VHD, p<.001 all variables. Conclusions: CAD is frequent in pts with VHD; its prevalence
has not decreased over time. In VHD, CAD increases MORT but CABG may not blunt this
risk. Additional data must define the basis for this apparent paradox and identify optimal
treatment options for this high-risk population.
1048-140 Accuracy of Presurgical Assessment of Myxomatous 
Mitral Valve Pathology Using Real-Time Three-
Dimensional Echocardiography
Lissa Sugeng, Yan Katsnelson, Lynn Weinert, R. Parker Ward, Kirk T. Spencer, Jeanne 
M. DeCara, Victor Mor-Avi, Valluvan Jeevanandam, Roberto M. Lang, University of 
Chicago, Chicago, IL
Transesophageal echocardiography (TEE) aids in the presurgical planning of mitral valve
(MV) disease, however, multiple views are required to delineate the exact location of the
MV pathology. Although three-dimensional echocardiography (3DE) provides unique
views of the MV, previous methods have been tedious and time consuming. The availabil-
ity of real-time transthoracic imaging technology overcomes these limitations. Our goal
was to evaluate the accuracy of real-time transthoracic 3DE using a newly developed full
matrix array probe (x4, Philips) in detecting MV pathology when compared to TEE, using
surgical confirmation as a gold standard. Method. 12 patients undergoing TEE evalua-
tion prior to mitral valve surgery were studied. Real-time 3DE images of the MV were
obtained from parasternal and apical windows. Images were interpreted by a reader
blinded to the results of TEE and surgical diagnoses. Results. 10/12 patients (83%) had
adequate 3D image quality for interpretation. 3DE accurately detected abnormal MV seg-
ments in 9/10 patients, but failed to detect abnormal A1 and A3 segments of the MV in
one patient. TEE failed to correctly diagnose 2 patients. In one patient, a perforated ante-
rior leaflet was misinterpreted. In the second patient, TEE incorrectly interpreted the
extent of a P2 lesion. Conclusion. Compared with surgical findings, real-time 3DE has
diagnostic ability comparable to that of TEE in detecting abnormal MV segments, but with
an important advantage of being less invasive. 
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1067-135 Over-Expression of Fibronectin Involves Activation of 
Mitogen-Activated Protein-Kinase-Kinase of the Stress 
Activated Protein Kinase/C-Jun N-Terminal Kinase in 
Aortic Regurgitation
Sharada L. Truter, Themy F. Dumlao, Eungsuk Lee, Zhen Huang, Jeffrey S. Borer, Weill 
Medical College of Cornell University, New York, NY
Background: Experimentally and clinically, chronic aortic regurgitation (AR) causes
myocardial fibrosis with hyperproduction of fibronectin (FN) by cardiac fibroblasts (CF).
Using cultured CF, we’ve shown increased activation of c-Jun N-terminal kinase (JNK-1)
of the MAPK cascade in AR, with consistent increases in reaction products. This sug-
gests that the MEKK-MEK-JNK signaling module of MAPK could mediate increased FN
expression in AR. To test this, we assessed MEK-4 and MEK-7 activity by assaying phos-
phorylation of JNK-1 protein in NL-CF and AR-CF. Methods: MEK-4 and MEK-7 were
immunoprecipitated from lysates of CF cultures (passage 6) from 5 pairs of NL and AR
NZW rabbit hearts, then incubated for 30 min in kinase buffer containing 32P-γ-ATP with
recombinant JNK-1 protein. Samples were separated by SDS-PAGE, dried and autorad-
iographed. Relative phosphorylation of JNK-1 by MEKs was assessed by videodensitom-
etry. Results: JNK-1 phosphorylation was increased when immunopreciptated with
MEK-4 or MEK-7 [1.7: 1, p=.005, and 1.8: 1, p=.001]; the increase was seen in 5/5 AR-
CF vs NL-CF (Table); activity of both MEKs varied directly with regurgitant fraction(RF)
[r2=.7; p=.08 for MEK-4 and r2=.87; p=.05 for MEK-7]. Conclusion: Chronic severe AR
stimulates MEK-4/7 causing JNK-1 activation and increasing FN expression by AR-CF.
Though confirmation is needed by testing effects of pathway inhibitors, these results sug-
gest possible novel pharmacologic interventions to mitigate fibrosis in AR. 
